- Home
- IMUX vs INFU Comparison
IMUX vs INFU Comparison
Compare IMUX & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | INFU |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 197.0M |
| IPO Year | 2013 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IMUX | INFU |
|---|---|---|
| Price | $12.97 | $12.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $36.00 | $15.00 |
| AVG Volume (30 Days) | ★ 196.4K | 97.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 181.82 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $143,436,000.00 |
| Revenue This Year | N/A | $3.20 |
| Revenue Next Year | N/A | $7.31 |
| P/E Ratio | ★ N/A | $60.50 |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $0.51 | $7.29 |
| 52 Week High | $17.43 | $12.97 |
Technical Indicators
Market Signals| Indicator | IMUX | INFU |
|---|---|---|
| Relative Strength Index (RSI) | 28.95 | 60.82 |
| Support Level | $11.21 | $11.79 |
| Resistance Level | $15.82 | $12.97 |
| Average True Range (ATR) | 1.17 | 0.30 |
| MACD | -0.43 | -0.11 |
| Stochastic Oscillator | 7.58 | 43.66 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.